These include a history of pancreatitis, severe gastrointestinal conditions such as gastroparesis, gallbladder disease, and reduced kidney function, where dehydration from vomiting or diarrhea is the main concern
2008, 59 (Suppl 7): 19-30
Convenience: Simplifies your supplement regimen with a once-a-day formula, making it easy to incorporate into your daily routine
Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose
Eli Lilly's tirzepatide products, Mounjaro and Zepbound, are growing fast in market share and are projected to overtake semaglutide as the leading GLP-1 drug within the next few years, though semaglutide still holds the largest overall proportion at the time of writing